Schulze-TopphoffUPratAProzorovskiTet al. Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med2009; 15: 788–793.
2.
SteinmanL.Blocking adhesion molecules as therapy for multiple sclerosis: Natalizumab. Nat Rev Drug Discov2005; 4: 510–518.
3.
TradtrantipLZhangHSaadounSet al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol2012; 71: 314–322.
4.
BittnerSRuckTFernandez-OrthJet al. TREK-king the blood-brain-barrier. J Neuroimmune Pharmacol2014; 9: 293–301.
5.
LarochelleCAlvarezJIPratA.How do immune cells overcome the blood-brain barrier in multiple sclerosis?FEBS Lett2011; 585: 3770–3780.
6.
JacobsJM.Vascular permeability and neurotoxicity. Environ Health Perspect1978; 26: 107–116.
7.
MartinAJFristonKJColebatchJGet al. Decreases in regional cerebral blood flow with normal aging. J Cereb Blood Flow Metab1991; 11: 684–689.
ZippFAktasO.The brain as a target of inflammation: Common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci2006; 29: 518–527.
10.
DisantoGBarroCBenkertPet al. Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol2017; 81: 857–870.
11.
SillerNKuhleJMuthuramanMet al. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Mult Scler J. Epub ahead of print 15March2018. DOI: 10.1177/1352458518765666.
12.
BranisteVAl-AsmakhMKowalCet al. The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med2014; 6: 263ra158.
13.
AbsintaMHaSKNairGet al. Human and nonhuman primate meninges harbor lymphatic vessels that can be visualized noninvasively by MRI. Elife2017; 6: e29738.
14.
PetrovaTVKohGY.Organ-specific lymphatic vasculature: From development to pathophysiology. J Exp Med2018; 215: 35–49.
